MVision’s AI segmentation service has been updated and now supports new Lung SABR protocol and MRI Male Pelvis protocol MR-only workflow

Helsinki – June 8, 2021 – MVision will be releasing an important update to segmentation service that standardizes organ-at-risk contouring and automates segmentation in radiotherapy to streamline cancer treatment planning. The update is scheduled to take place between June 12th-June 13th.

MVisions’ Chief Product Officer and medical physicist, Jarkko Niemelä, further emphasized the importance of the new lung CT model, stating that, “During the pandemic, there has been a growing need for shorter and more efficient radiation therapy. Many lung cancer patient groups can be treated with stereotactic radiotherapy where, instead of conventional 20 to 33 visits, the patient has 3 or 4 treatment fractions. We wanted to support this growing need and developed a SABR Consortium guideline compliant lung CT auto-segmentation model.”

The update will include 2 segmentation models:

  • An advanced lung CT model following the lung SABR protocol
  • A Male pelvis MRI model for MRI-only treatment planning workflow supporting major MRI scanners

Furthermore, additions will be made to existing models, including the:

  • Male pelvis CT: Kidneys
  • Abdomen-lung CT: SpinalCord
  • Breast CT: Carotids, Thyroid and SpinalCord
  • Female pelvis CT: Bony structures and bowels

Mahmudul Hasan, MVision AI’s co-founder and CEO, expressed his excitement in the new release of the Lung and pelvis models. He disclosed that, “the new Lung SABR and MR pelvis model (MR-only) release is a significant milestone to support SBRT and MR Only workflow. I am thankful to our existing partners and the team for delivering this within a short period of time.”

For more information on the MVision AI Segmentation Service 1.2.1, contact Dr. Britta Schürmann, Head of Sales Development, EMEA.

About MVision AI:

MVision is a Helsinki-based company operating globally. The company was born out of a deep desire to harness AI in winning the war on cancer. MVision AI exists to provide clinicians with the finest, most reliable tools to improve clinicians’ workflow and help them to focus on patient care.

For more information, contact MVision AI

c/o Terkko Health Hub, Haartmaninkatu 4, 00290 Helsinki, Finland.

Tel: +358 (0) 40 5489 229

Email: info (at)


+358 40 500 7915; pr (at)

Our Newsletter

Subscribe to get information, latest news and other interesting offers about MVision AI

Related Posts


MVision AI Appoints Antti Pirskanen as New Chief Financial Officer

Helsinki, Finland – June 14, 2024 – MVision AI, a pioneering company in the development of innovative AI solutions for radiation oncology is pleased to announce the appointment of Antti Pirskanen as its new Chief Financial Officer (CFO). Antti will assume his responsibilities immediately, bringing extensive expertise in financial management…

Press Releases


MVision AI Receives MFDS Approval and Market Authorization for South Korea

HELSINKI, Finland – June 14, 2024 MVision AI is pleased to announce that our application for MVision AI Segmentation (Contour+) in South Korea has been accepted by the Ministry of Food and Drug Safety (MFDS) under the “Image Segmentation Application Software” for image analysis algorithms to be used in radiation…

Press Releases


From Awareness to Action: International Men’s Health Week and Cancer Screening

This year, from 10 to 16 June we celebrate the International Men's Health Week. The dates are different each year, so it precedes and includes Father's Day. Multiple activities around the world aim to raise awareness of men’s preventable health problems and early detection (1). The official framework was created…